Q-omics provides the consensus-scored EFCAB7 profile across patient tissues and cancer cell-line models. EFCAB7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, EFCAB7 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, EFCAB7 RNA expression shows 21,418 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, and UVM as cancer lineages where EFCAB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFCAB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFCAB7 survival associations across molecular data types. EFCAB7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFCAB7 RNA expression–survival associations across cancer types. High EFCAB7 expression shows unfavorable associations in KICH, LIHC, LGG and ESCA, but favorable associations in KIRC and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for EFCAB7 RNA expression.
This table summarizes EFCAB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EFCAB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFCAB7 shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in LIHC, COAD and CHOL. The KICH box plot shows higher EFCAB7 RNA expression in normal versus tumor tissue (log2 FC = −1.511, t-test p < 0.001).
This table shows molecular features associated with EFCAB7 in patient tissues and cancer cell lines. In patient samples, EFCAB7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, EFCAB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
